Publication
title
Pharmaceutical Pricing and Reimbursement in Canada: An Overview for Innovative Drug Manufacturers
AUTHOR(S)
DATE
January 29, 2010
EXPERTISE
The pricing and reimbursement of innovative pharmaceuticals in Canada is controlled at three levels: by the federal Patented Medicine Prices Review Board, by the 17 federal, provincial and territorial public drug plans and by the Common Drug Review. This system means that an innovative manufacturer must obtain the approval of 19 different bodies for the price of a new drug in Canada. Needless to say, navigating through this labyrinth of pricing regimes poses a significant challenge to drug manufacturers and impairs Canadians' access to innovative medicines. The purpose of this article is to provide international practitioners with an introduction to the various pricing and reimbursement bodies in Canada, and to highlight emerging issues and trends in the area.
Click here to read the article in PDF.
The purpose of this document is to provide information as to developments in the law. It does not contain a full analysis of the law nor does it constitute an opinion of Ogilvy Renault LLP or any member of the firm on the points of law discussed.
Contacts
Penny Bonner
Toronto
416.216.6629
pbonner@ogilvyrenault.com
Profile
Jill Daley
Toronto
416.216.1930
jdaley@ogilvyrenault.com
Profile
